Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2161 to 2170 of 2607 total matches.

Dexfenfluramine for Obesity

   
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996  (Issue 979)
that long-term (more than three months) use of these drugs increased the risk of PPH from 1-2 per million ...
Dexfenfluramine (Redux - Wyeth-Ayerst) has been approved by the US Food and Drug Administration as an aid to diet for treatment of obesity and maintenance of weight loss. Dexfenfluramine is the dextrorotatory isomer of d,l-fenfluramine (Pondimin), which has been marketed for short-term weight reduction for many years and recently has been widely used in combination with phentermine (Ionamin, and others), a sympathomimetic drug (Medical Letter, 36:107, 1994).
Med Lett Drugs Ther. 1996 Jul 19;38(979):64-5 |  Show IntroductionHide Introduction

Midodrine for Orthostatic Hypotension

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 1997  (Issue 1003)
), an alpha 1 -selective adrenergic agonist, is now available for treatment of severe symptomatic ...
Midodrine hydrochloride (ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition include other sympathomimetics, constrictive garments, erythropoietin (Epogen; Procrit) and fludrocortisone with salt (D Robertson and TL Davis, Neurology, 45 suppl 5: S26, 1995).
Med Lett Drugs Ther. 1997 Jun 20;39(1003):59-60 |  Show IntroductionHide Introduction

Tizanidine for Spasticity

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997  (Issue 1004)
and completely absorbed, especially in the presence of food. Plasma concentrations reach a peak in about 1 ...
Tizanidine (Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe and Japan for 12 years as a short-term muscle relaxant.
Med Lett Drugs Ther. 1997 Jul 4;39(1004):62-3 |  Show IntroductionHide Introduction

Bupropion (Zyban) for Smoking Cessation

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 1997  (Issue 1007)
with doses up to 300 mg per day has been only about 0.1%. The incidence might be higher in patients ...
Bupropion hydrochloride, currently available as an antidepressant (Wellbutrin - Medical Letter, 31:97, 1989; Wellbutrin SR), is now being marketed in a sustainedrelease formulation as Zyban (Glaxo Wellcome) for use as an aid in smoking cessation.
Med Lett Drugs Ther. 1997 Aug 15;39(1007):77-8 |  Show IntroductionHide Introduction

Tolcapone for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998  (Issue 1028)
decrease in "off" time of 1.4 hours (20%) with placebo, 2.3 hours (32%) with 100 mg t.i.d. of tolcapone ...
Tolcapone (Tasmar - Roche), a dihydroxy-methyl-nitrobenophenone, has been marketed as an adjunct to levodopa/carbidopa (Sinemet, and others) for treatment of Parkinson's disease in both stable patients and those with end-of-dose "wearing off"of levodopa.
Med Lett Drugs Ther. 1998 Jun 5;40(1028):60-1 |  Show IntroductionHide Introduction

Rituximab for Non-Hodgkins Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998  (Issue 1029)
of 400 mg/hr. The cost to the pharmacist for 4 weekly infusions in a 1.7-m 2 patient is about $11,000 ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Med Lett Drugs Ther. 1998 Jun 19;40(1029):65-6 |  Show IntroductionHide Introduction

Thalidomide

   
The Medical Letter on Drugs and Therapeutics • Oct 23, 1998  (Issue 1038)
inhibition of the synthesis of tumor necrosis factor-α (JM Tramontana et al, Mol Med, 1:384, 1995). The drug ...
Thalidomide (Thalomid - Celgene), a synthetic derivative of glutamic acid, has been approved by the FDA for use in treatment of leprosy. Thalidomide was marketed in Europe in 1957 as a sedative but withdrawn four years later after being associated with severe human teratogenicity. The drug has since been found to be effective for several different indications.
Med Lett Drugs Ther. 1998 Oct 23;40(1038):103-4 |  Show IntroductionHide Introduction

Candesartan for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 1998  (Issue 1040)
— Candesartan, like irbesartan, losartan and valsartan, blocks the binding of angiotensin II to type 1 ...
Candesartan cilexetil (Atacand - Astra) is the fourth angiotensin II receptor antagonist to become available in the USA for oral treatment of hypertension.
Med Lett Drugs Ther. 1998 Nov 20;40(1040):109-10 |  Show IntroductionHide Introduction

Cevimeline (Evoxac) For Dry Mouth

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
at 1000 Main Street, New Rochelle, NY 10801-7537. Subscription fees: 1 year, $49.00; 2 years, $82.00; 3 ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Med Lett Drugs Ther. 2000 Aug 7;42(1084):70 |  Show IntroductionHide Introduction

PC Spes

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
at 1000 Main Street, New Rochelle, NY 10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 ...
PC Spes, a dietary supplement sold for "prostate health", is being used increasingly to treat prostate cancer.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):15-6 |  Show IntroductionHide Introduction